Sign in
CompletedNo phase

Flash Glucose Monitoring Targets in Gestational Diabetes

Key facts

Who runs it
University Medical Centre Ljubljana
Where
Slovenia1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
205 people enrolled
Started
1 Dec 2022
Ended
1 Feb 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Use of FreeStyle Libre 14 day Flash Glucose Monitoring System
Record updated
19 August 2025

Who can take part

Age
18 years to 40 years
Sex
Women only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Pregnant women treated at the Diabetes Outpatient Clinic of the Clinical Department of Endocrinology, Diabetes, and Metabolic Diseases for gestational diabetes (GDM),
  • Agreement with the study protocol and ability to follow the study protocol,
  • Diagnosis of GDM established using the standard recommended OGTT method between the 24th and 28th weeks of pregnancy,
  • Age between 18 and 40 years

Who cannot take part

  • Treatment with systemic corticosteroids for more than 14 days prior to inclusion in the study,
  • History of bariatric surgery,
  • Hospitalization for psychiatric illness within the last year,
  • First visit to the Diabetes Outpatient Clinic after the 34th week of gestation
  • Multiple pregnancy,

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The use of glucose monitoring sensors is already well-established in pregnant women with type 1 diabetes (T1D), where it has been proven to improve glycemic control and perinatal outcomes. However, it has not yet been sufficiently researched in the area of gestational diabetes (GDM). Some smaller studies have shown a favorable effect on glycemic control, but no statistically significant differences were observed in reducing perinatal complications. A randomized, prospective study will include 200 pregnant women with GDM, treated at the Diabetes Outpatient Clinic of the Clinical Department of Endocrinology, Diabetes, and Metabolic Diseases at the University Medical Centre Ljubljana. Participants will be divided into two groups. The first group will measure subcutaneous glucose using FSL in addition to self-monitoring of blood glucose (SMBG) while fasting and 60 minutes after main meals at the same time intervals. In both groups, glycemic targets, maternal outcomes, and neonatal outcomes will be monitored. In the FSL + SMBG group, sensor parameters for glycemic control will also be tracked.

The 2 groups in the trial

  • Pregnant women with GDM using FGM and SMBGTreatment being tested

    Pregnant women with GDM using Flash Glucose Monitoring (FGM) and Self-Monitoring of Blood Glucose (SMBG)

    Treatment: Use of FreeStyle Libre 14 day Flash Glucose Monitoring System

  • Pregnant women with GDM using only SMBGExisting treatment, for comparison

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Record updated
19 August 2025